Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003801 | 0.81 | PTGDR2 (0.45) | ACLYKDM4EMAPTTHRBPTGDR2 | |
| SCHEMBL22005104 | 0.80 | KDM4E (0.50) | ACLYPTGS2GRIK2TACR1KDM4E | |
| SCHEMBL22004308 | 0.78 | RAB9A (0.48) | ACLYKDM4EMAPTTHRBPTGDR2 | |
| SCHEMBL13222023 | 0.75 | MAPT (0.51) | PTGS2MAPTTHRBPTGDR2HTT | |
| SCHEMBL11601877 | 0.72 | CASR (0.67) | PTGS2EGFRNR1I2ADRA2AADORA3 | |
| SCHEMBL22004380 | 0.72 | ACLY (0.58) | ACLYKDM4EMAPTPTGDR2PLA2G4A | |
| SCHEMBL9539031 | 0.70 | KDM4E (0.44) | KDM4EMAPTCASP1CASP7RAB9A | |
| SCHEMBL9539113 | 0.70 | KDM4E (0.48) | PTGS2KDM4EMAPTCASP1CASP7 | |
| SCHEMBL22003798 | 0.70 | ACLY (0.44) | ACLYMAPTTHRB | |
| SCHEMBL29839883 | 0.70 | ACLY (0.64) | ACLYPTGS2LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885PTGS2 4122/4885GRIK2 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.